UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

Current Report Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): **June 14, 2019**

THERAVANCE BIOPHARMA, INC.

(Exact Name of Registrant as Specified in its Charter)

Cayman Islands	**001-36033**	**Not Applicable**
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification Number)

PO Box 309
Ugland House, South Church Street
George Town, Grand Cayman, Cayman Islands KY1-1104
(650) 808-6000
(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	**Trading Symbol(s)**	**Name of each exchange on which registered**
Ordinary Share $0.00001 Par Value	TBPH	NASDAQ Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 7.01. Regulation FD Disclosure.

The information in this Current Report (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report (including Exhibit 99.1) shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

On June 14, 2019, members of the Theravance Biopharma, Inc. management team will be participating in a webinar hosted by Evercore ISI in New York, New York. A copy of the slide presentation is being furnished pursuant to Regulation FD as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1	Slide deck entitled Investor Presentation - Evercore ISI Webinar- dated June 2019

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

THERAVANCE BIOPHARMA, INC.

Date: June 14, 2019

By: /s/ Bradford J. Shafer
Bradford J. Shafer
Executive Vice President, General Counsel and Secretary

Exhibit 99.1


Theravance Biopharma, Inc.
(NASDAQ: TBPH)
Investor Presentation
Evercore ISI Webinar
June 14, 2019
Theravance Biopharma
Medicines That Make a Difference®
THERAVANCE®, the Cross/Star logo, and MEDICINES THAT MAKE A DIFFERENCE® are registered trademarks of the Theravance Biopharma group of companies.
YUPELRI® is a United States registered trademark of Mylan Specialty L.P. All third party trademarks used herein are the property of their respective owners.
© 2019 Theravance Biopharma. All rights reserved.

Forward Looking Statements

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward-looking statements or projections made by the company are subject to risks and uncertainties that may cause actual results to differ materially from the forward-looking statements or projections.

Examples of forward-looking statements in this presentation may include the current dispute with Innoviva, Inc. and TRC LLC, statements relating to the company's strategies, plans and objectives, the company's regulatory strategies and timing of clinical studies (including the data therefrom), the potential characteristics, benefits and mechanisms of action of the company's product and product candidates, the potential that the company's research programs will progress product candidates into the clinic, the company's expectations for product candidates through development, potential regulatory approval and commercialization (including their differentiation from other products or potential products), product sales or profit share revenue and the company's expectations for its 2019 operating loss, excluding share-based compensation.

The company's forward-looking statements are based on the estimates and assumptions of management as of the date of this presentation and are subject to risks and uncertainties that may cause the actual results to be materially different than those projected, such as risks related to the nature of the current dispute with Innoviva and TRC LLC, the uncertainty of arbitration and litigation and the possibility that an arbitration award or litigation result involving the current dispute could be adverse to the company, delays or difficulties in commencing or completing clinical studies, the potential that results from clinical or non-clinical studies indicate product candidates are unsafe or ineffective (including when our product candidates are studied in combination with other compounds), delays or failure to achieve and maintain regulatory approvals for product candidates, risks of collaborating with third parties to discover, develop and commercialize products, risks associated with establishing and maintaining sales, marketing and distribution capabilities.

Other risks affecting the company are described under the heading "Risk Factors" and elsewhere in the company's Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 10, 2019, and other periodic reports filed with the SEC.

Theravance Biopharma Strategic Objective

Transform the treatment of serious diseases with novel, locally acting organ-selective therapies

Organ-selective Approach

COMPOUNDS DESIGNED TO FULLY HARNESS INTENDED BIOLOGY

Conventional Systemic Compound

- Often unable to achieve maximal efficacy due to dose-limiting safety
- Narrow therapeutic index

Theravance Biopharma Organ-selective Compound

- Opportunity to increase dose for improved efficacy, without cost of systemic safety risk
- Expanded therapeutic index

Illustrated example: lung selectivity

Portfolio of Organ-selective Projects

LUNG	*GI*	*EYE*
COPD	Crohn's Disease	Diabetic Macular Edema (DME)
Moderate-Severe Asthma	Ulcerative Colitis	
Lung Transplant Rejection	Celiac Disease	
Idiopathic Pulmonary Fibrosis (IPF)		


YUPELRI® (revefenacin)
inhalation solution
Nebulized long-acting muscarinic antagonist (LAMA)

YUPELRI®: Formal Commercial Launch Underway

FDA-APPROVED FOR THE MAINTENANCE TREATMENT OF COPD

- *First and only once-daily bronchodilator delivered in a nebulizer*
- *Higher of two doses approved: 175 mcg once daily, for use with any standard jet nebulizer*

Unmet need for nebulized LAMA therapy

- Once-daily LAMAs are first-line therapy for moderate to severe COPD [1]
- No once-daily nebulized LAMAs available previously; only available in handheld devices
- Nebulized therapy associated with reduced hospital readmissions in low PIFR patients [2]

YUPELRI® (revefenacin) inhalation solution. Approved for the maintenance treatment of patients with COPD. COPD = Chronic Obstructive Pulmonary Disease.
[1] Global Strategy for Diagnosis, Management, and Prevention of COPD. [2] Suboptimal Inspiratory Flow Rates Are Associated with COPD and All Cause Readmissions. Loh et al., Annals of ATS 2017.

Compelling Need for Once-Daily Nebulized LAMA

ENDURING PATIENT NICHE AND SIGNIFICANT MARKET OPPORTUNITY

Enduring patient niche

- 9% of COPD patients currently use nebulizers for ongoing maintenance therapy [1]
- >100M patient treatment days in nebulized COPD segment [2]
- 41% of COPD patients use nebulizers at least occasionally for bronchodilator therapy [1]
- Pricing in branded LA nebulized segment ~ 2x handheld Spiriva [2]

Significant market opportunity

- YUPELRI® may be complementary to existing nebulized LABA treatments
- Mylan partnership brings commercial strength in nebulized segment

Theravance Biopharma
Medicines That Make a Difference

[1] TBPH market research (N = 160 physicians); Refers to US COPD patients. [2] IMS Health information service: NSP for period MAT May, 2015. Excludes nebulized SABAs. IMS expressly reserves all rights, including rights of copying, distribution and republication.

Partnership with Mylan Brings Commercial Strength in Nebulized Opportunity

Combined sales infrastructures cover
Hospital, Hospital Discharge and Home Health settings

Targeting HCPs at key intersections in the patient's disease management process

- Hospital is an important site of care for patients with worsening of COPD symptoms
- Theravance Biopharma's established hospital-focused sales force is targeting the inpatient setting
- Theravance Biopharma partners with institutions to transition appropriate patients from hospital to home on YUPELRI®
- Mylan's role is to ensure patients remain on YUPELRI® for maintenance therapy in the outpatient setting

Use of YUPELRI® Consistent with GOLD Guidelines

LAMAs RECOMMENDED AS FIRST-LINE TREATMENT [1]

Use of a nebulized treatment is optimal for many COPD patients

- At least 2/3 of patients make at least one error using an inhaler device, many critical to delivery of medication [2]
- Main errors in delivery device use relate to problems with inspiratory flow, inhalation duration, coordination, etc.
- Choice of inhaler depends on access, cost, prescriber and most importantly, patient ability and preference

COPD is associated with many risk factors for difficulty using an inhaler device [3]

- Older age and arthritic hands
- Muscle weakness and impaired diaphragm function which can limit inspiratory force
- Dyspnea which makes breath holding challenging
- Cognitive dysfunction and dementia which increases the risk of incorrect MDI/DPI use

YUPELRI®: First and only once-daily nebulized LAMA

✓ Once-daily dosing (via any standard jet nebulizer)	✓ Proven 24-hour control
✓ Demonstrated safety profile	✓ Up to 100% of Medicare Part B patients covered

[1] Global Strategy for Diagnosis, Management, and Prevention of COPD. [2] GOLD 2019. [3] Tashkin 2017.

Insufficient Peak Inspiratory Flow Rate (PIFR) Associated with Increased Burden

PIFR is the measure of patient inspiratory effort during a maximal effort

- Effective DPI use requires patients generate sufficient inspiratory flow rate to overcome internal resistance of a particular devise in order to deaggregate powdered drug into fine particles for optimal peripheral airway and lung deposition

Suboptimal PIFR has been observed in significant proportion of patients with COPD

- 19%–25% of stable outpatients [1]
- 32%–52% of inpatients pre-discharge for COPD exacerbation [2]

Patients with suboptimal PIFR also associated with:

- More respiratory infections in previous 12 months
- Lower lung function (% Predicted FVC)
- More severe symptoms [3]
- Smaller lung size (female, shorter height)
- Increased risk of re-hospitalization [2]

	Optimal PIFR				Sub-optimal PIFR			
Mahler et al ATS 2019	Total (N = 252)	GOLD 2 (n = 159)	GOLD 3 (n = 78)	GOLD 4 (n = 15)	Total (N = 273)	GOLD 2 (n = 78)	GOLD 3 (n = 82)	GOLD 4 (n = 113)
mMRC ≥2, n (%)	123 (49)	71 (45)	40 (51)	12 (80)	191 (70)	40 (51)	59 (72)	92 (81)
mMRC, mean (SD)	1.6 (1.0)	1.4 (1.0)	1.7 (0.9)	2.1 (0.8)	2.1 (1.0)	1.6 (0.9)	2.1 (1.0)	2.4 (0.9)
BDI, mean (SD)	6.1 (2.0)	6.3 (2.0)	5.6 (1.8)	5.4 (1.8)	5.1 (2.0)	5.9 (2.1)	5.0 (1.9)	4.7 (1.7)

YUPELRI® Launch Update

ENCOURAGING INITIAL MARKET RESPONSE

FORMULARY

32 Wins
(equates to 104 accounts)

~80 Reviews Scheduled
(~320 potential accounts)

100% medical support requests **fulfilled** <30 days

PATIENT

Field force productivity goals exceeded

~4,500 patients prescribed
(thru 1Q19)

ACCESS

100% Medicare Part B [1]

~50% Commercial

Permanent J-CODE issued
(effective July 1, 2019)

- Majority of YUPELRI® volume flows through durable medical equipment (DME) channel [2]; remaining volume flows through hospitals, retail and long-term care pharmacies
- WAC: $1,030 per month (or ~$34 per day)

[1] For patients with supplemental insurance
[2] Approximately 3 month lag in data capture

Opportunity for YUPELRI® (revefenacin) in China

POTENTIAL TO ADDRESS LARGE AND UNDERSERVED COPD PATIENT POPULATION

Expansion of development and commercialization agreement

- Mylan granted exclusive development and commercialization rights to revefenacin in China and adjacent territories
- Theravance Biopharma eligible to receive:
  - $18.5 million upfront payment
  - Up to $54 million in additional potential development and sales milestones
  - Tiered royalties on net sales, if approved
- Mylan responsible for all aspects of development and commercialization in partnered regions

Significant market opportunity

- COPD affects ~100 million individuals in China[1]
- ~43% of COPD patients suffer from moderate to very severe forms of disease[2]
- COPD is one of the top three causes of death in China[3] and presents significant financial burden to healthcare system[2]

Theravance Biopharma and Mylan strategic collaboration

- In 2015, the companies established a strategic collaboration to develop and commercialize nebulized revefenacin products for COPD and other respiratory diseases
  - Theravance Biopharma eligible to receive up to $259 million in potential development and sales milestone payments, as well as profit-sharing arrangement with Mylan on US sales and tiered royalties on ex-US sales
  - Theravance Biopharma retains worldwide rights delivered through other dosage forms, including metered dose inhaler and dry powder inhaler (MDI/PDI)

Theravance Biopharma
Medicines That Make a Difference

[1]C. Wang, J. Xu, L. Yang et al., "Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study," The Lancet, vol. 391, no. 10131, pp. 1706–1717, 2018. [2] Fang L, Gao P, Bao H, et al., "Chronic obstructive pulmonary disease in China: a nationwide prevalence study," Lancet Respir Med 2018; 6: 421–430. [3] Yin P, Wang H, Vos T, et al., "A subnational analysis of mortality and prevalence of COPD in China From 1990 to 2013: Findings from the global burden of disease study 2013," Chest. 2016;150:1269–1280.

NDA Supported by Positive Phase 3 Results

TWO REPLICATE EFFICACY STUDIES, PLUS 12-MONTH SAFETY STUDY



- Primary endpoint achieved in replicate efficacy studies
  - Robust and sustained improvements in FEV_1, 24 hour efficacy
  - Study included use as monotherapy as well as add-on to LABA or LABA/ICS
- Generally well tolerated in 12-month safety study

Theravance Biopharma
Medicines That Make a Difference

Pooled analysis.
Effective as single agent or on top of LABA or LABA/ICS

Consistent Treatment Effect Maintained for 24 Hours with QD Dosing in Phase 3 Efficacy



Dose dependent effect on FEV_1 with 175 consistently better than 88 mcg

Theravance Biopharma
Medicines That Make a Difference

Source: Phase 3 efficacy studies of revefenacin (TD-4208).
PD: pre-dose.
Note: 24-hour spirometry was assessed at baseline and after 12 weeks' treatment in a subset of subjects in both studies.

Low Incidence of Adverse Events and Comparable to Placebo in Phase 3 Efficacy

Description	Placebo (N=418)	88mcg (N=417)	175mcg (N=395)
Serious Adverse Events	21 (5%)	21 (5%)	15 (4%)
Deaths:			
- Homicide	0 (0%)	0 (0%)	1 (0.2%)
- Sudden death[1]	1 (0.2%)	0 (0%)	0 (0%)
Adverse Events (AEs)	206 (49%)	226 (54%)	203 (51%)
Possibly/probably Related AEs	39 (9%)	33 (8%)	41 (10%)
AEs Leading to Study Drug Discontinuation	59 (14%)	50 (12%)	43 (11%)

n=1229 unique subjects; 1 subject was randomized to 175 mcg but also received placebo; this subject is counted in both groups in the safety population

Source: Phase 3 efficacy studies of revefenacin (TD-4208).
[1] Sudden death in placebo group attributed as cardiovascular by independent adjudication.

Most Frequently Reported Adverse Events (AEs) in Phase 3 Efficacy Studies

Description	Placebo (N=418)	88 mcg (N=417)	175 mcg (N=395)
Exacerbation of COPD	48 (11.5%)	42 (10.1%)	42 (10.6%)
Cough	17 (4.1%)	17 (4.1%)	17 (4.3%)
Dyspnea	23 (5.4%)	13 (3.1%)	12 (3.0%)
Headache	11 (2.6%)	21 (5.0%)	16 (4.1%)

n=1229 unique subjects; 1 subject was randomized to 175 mcg but also received placebo; this subject is counted in both groups in the safety population

- No reports of worsening of urinary retention, blurred vision or narrow-angle glaucoma
- Dry mouth reported in <0.5% of patients on revefenacin

TD-1473 JAK Inhibitor Program

Investigational oral gut-selective pan-Janus kinase (JAK) inhibitor for ulcerative colitis and other inflammatory intestinal diseases

Gut-selective Design

INFLAMMATION TREATED AT THE TISSUE OF INTEREST



Systemically available drug eliminated by the liver via first pass metabolism

TD-1473: Innovative Approach in Treating IBD

COMPELLING PRECLINICAL PACKAGE AND ENCOURAGING PHASE 1B DATA



Gut selectivity



Potent inhibition of Tyk2

Anti-inflammatory activity in disease model

Differentiated and Potential Breakthrough Approach

ADVANCING IN COLLABORATION WITH JANSSEN IN UC AND CROHN'S

TD-1473 program objectives: Oral pan-JAK inhibitor that distributes selectively throughout the intestines to treat inflammatory intestinal disease locally, with minimal systemic exposure or corresponding immunosuppressive effects, to enhance safety and efficacy



Encouraging Phase 1b study in UC patients

- Data demonstrated localized biological target engagement with minimal systemic exposure
- Clinical responses after only 4 weeks of therapy

Preclinical models of UC confirmed

- Improvements in diseases scores, local absorption and penetration of TD-1473 throughout intestinal tract

Phase 2 in Crohn's progressing and Phase 2b/3 study in UC underway

- FDA and EMA concur on Phase 2b/3 study design in ulcerative colitis

Encouraging Findings in Phase 1b Study

4-WEEK TREATMENT IN 40 PATIENTS WITH ULCERATIVE COLITIS

Key Findings

Favorable overall safety and tolerability	No systemic or opportunistic infections (including herpes zoster)
	No evidence of reduce white cell counts
Minimal systemic exposure	Plasma levels of TD-1473 very low
	Consistent in all cohorts to levels observed in healthy volunteers
Biologic activity in GI tract	**Endoscopic improvements and mucosal healing** reported in all active arms; none reported in placebo arm
	Rectal bleeding scores improved above placebo at highest two doses
	Rates of **clinical response** higher for all active doses compared to placebo[1]
	Clinical responses matched by **dose-dependent reductions in surrogate biomarkers**[2]
	Dose-related increases in local GI tissue drug concentrations; higher two doses produced mean concentrations above JAK IC50

Detailed results presented in oral late-breaker at UEGW 2018

Theravance Biopharma
Medicines That Make a Difference

[1] Clinical response as measured by both partial and full Mayo.
[2] Surrogate biomarkers include C-reactive protein (CRP) and fecal calprotectin.

TD-1473 Clinical Program

LATE-STAGE STUDIES IN ULCERATIVE COLITIS AND CROHN'S DISEASE

Phase 2b/3 study in ulcerative colitis

RHEA PROGRAM



Phase 2 study in Crohn's disease

DIONE STUDY

Global Collaboration Agreement for TD-1473

PURPOSED TO MAXIMIZE VALUE OF PROGRAM

Theravance Biopharma
Medicines That Make a Difference®

Janssen

- Shared belief in TD-1473 as gut-selective with potential to transform the treatment landscape in inflammatory intestinal disease
- Meaningful program enhancements
  - Accelerate clinical development and advance UC and Crohn's in parallel
  - Apply Janssen expertise in IBD to optimize clinical strategy and execution
  - Maximize worldwide commercial opportunity
- Attractive deal economics reducing overall financial risk
  - Deal value up to $1B milestones, including $100M upfront; additional profit-share in US

Collaboration with global leader in immunology represents milestone for TD-1473, our internally discovered pipeline and strategy to design organ-selective medicines


Ampreloxetine (TD-9855)
Investigational once-daily norepinephrine reuptake inhibitor
(NRI) for neurogenic orthostatic hypotension (nOH)

Symptomatic nOH Represents a Significant Unmet Need

nOH characterized by a sustained drop in blood pressure upon standing, due to body producing insufficient levels of norepinephrine (NE)

- Associated with several autonomic disorders: MSA, PD, PAF
- Symptoms include dizziness, fainting, blurred vision and weakness
- Orphan indication with < 200k patients in US

Opportunity exists for safe and effective treatment

- Only droxidopa (Northera) and midodrine FDA-approved for nOH
- Synthetic exogenous NE analogues impact disease by increasing vascular tone
- Limitations of current therapy: Supine hypertension, TID dosing, patients refractory or discontinue, lack of durability[1]
- Ideal therapy would target durable improvement in symptoms and daily function

Blood pressure key biological driver to nOH symptoms



Vasodilation lowers blood pressure

[1] Existing options associated with one or both therapies noted above; Northera prescribing information.
MSA: multiple system atrophy. PD: Parkinson's disease. PAF: pure autonomic failure. TID: three times per day.

NET Inhibition with Ampreloxetine Offers Potential to Restore Vascular Sympathetic Tone

A path to treating symptomatic nOH without introducing exogenous NE

- Blockade of NET in nOH patients inhibits endogenous neuronal NE uptake
- Increased levels of NE in the synapse cause vasoconstriction and a corresponding increase in blood pressure
- Increase in blood pressure improves symptoms
- Rationale for ampreloxetine in nOH
  - NRI with NE dominance confirmed in humans
  - QD dosing, long half-life, and metabolic profile for potential improved patient outcomes
  - Favorable safety and tolerability profile established in > 500 subjects[1]



[1] Includes Phase 1 SAD/MAD, elderly, and PET studies in healthy subjects and Phase 2a studies in fibromyalgia and ADHD patients.
NET: norepinephrine transporter. QD: once-daily.

Overview of Phase 2 Study in nOH

DESIGNED TO EVALUATE INITIAL AND DURABLE RESPONSE TO THERAPY

Three-part design in patients with nOH:

A
- Single-ascending dose portion of ampreloxetine (up to 20 mg)
- Testing blood pressure response to ampreloxetine

B
- Double-blind
- Placebo-controlled
- Single-dose (Part A response dose) or placebo

C
- Extension phase
- Open label design
- Up to 24 weeks (20 weeks dosing, 4 week wash out)
- Primary endpoint at 4 weeks

Patients started on Part A, and responders moved to Part B and/or Part C (extension phase)

Purpose: To evaluate the effect of ampreloxetine in improving blood pressure and key nOH symptoms

Part C: Responders in Part A eligible for open-label treatment for up to 5 months

- Designed to assess durability of effect
- Primary assessment at four weeks (Day 29)
- Efficacy evaluations: OHSA[1] #1, standing time duration, standing systolic blood pressure
- Also assessed safety and pharmacokinetics of ampreloxetine

Theravance Biopharma
Medicines That Make a Difference

[1] OHSA: Orthostatic Hypotension Symptom Assessment. OHSA #1 measures dizziness (cardinal symptom of nOH), lightheadedness, feeling faint, or feeling of impending black out.

Top-line Phase 2 Results in nOH

PARTS A and B: SINGLE-ASCENDING DOSE, AMPRELOXETINE OR PLACEBO

A Initial responses observed

Responses reported in majority of patients treated

- 27 of 34 patients enrolled in Part A showed improvements in SBP and/or standing time
- Responses observed above 5 mg

B Confirmation vs. placebo

Statistically significant difference of 30 mmHg at 4 hours post-dose (p = 0.011)

- Ampreloxetine increased SBP from a low baseline
- SBP dropped on placebo during day as expected, due to postural changes and eating
- No evidence of supine hypertension with ampreloxetine overnight

Part B change from baseline systolic blood pressure (n=10)



SBP: systolic blood pressure.

Top-line Phase 2 Results in nOH

PART C: REPEAT DOSE EXTENSION PHASE

C Durability of effect observed out to 4 weeks

16 of 21 patients (76%) completed four weeks of treatment

Reductions in symptom severity, with most pronounced benefit in patients with symptomatic nOH[1]

- Mean reduction in OHSA #1 = 2.4 points at four weeks (n=16)
- 13 completers had OHSA #1 > 4 points at baseline; **mean reduction in group = 3.8 points at four weeks**

Consistent increases in SBP through four weeks

- Clinically meaningful increases in standing SBP (7 mmHg or greater) after standing for three minutes at all time points on all weekly clinic visits

Generally well tolerated; no serious adverse events assessed as drug-related

Registrational Phase 3 program in symptomatic nOH progressing

[1] Symptomatic defined as OSHA #1 > 4.

Ampreloxetine Clinical Program

PHASE 3 REGISTRATIONAL PROGRAM IN SYMPTOMATIC NOH



Supportive 5-month treatment data from Phase 2 study to be presented at IAPRD and ENC

TD-8236

Investigational, lung-selective inhaled JAK inhibitor for moderate-to-severe asthma regardless of Th2 phenotype

High Medical and Economic Burden in Uncontrolled Asthma

Patient population

- 4.9M moderate-to-severe diagnosed patients in US[1]

Current treatments

- Inhaled steroids, which often fail to control disease
- Approved biologics affect subsets of patients

Burden of disease

- Acute exacerbations lead to ER visits
- Uncontrolled symptoms interfere with ability to sleep, work and QOL
- US medical costs estimated to be $58B[3]
- Disproportionate healthcare utilization by severe and uncontrolled asthmatics
  - High frequency of hospitalizations and increased use of systemic medications

Small portion of US patients cause high proportion of cost



[2] Sadatsafavi, M., et al. Can Respir J. 2010 17(2): 74-80.
[3] Nurmagambetov, T., et al., Ann Am Thorac Soc. 2018.

TD-8236: Lung-selective pan-JAK Inhibitor

POTENTIAL TO ADDRESS PATIENTS' NEEDS REGARDLESS OF TH2 PHENOTYPE

Patient heterogeneity in severe asthma



JAK/STAT cytokines implicated in severe asthma

Th2-high	Th2-low
IL-4	**IL-23**/IL-12
IL-13	**IL-6**
IL-5	IL-27
TSLP	IFN-γ

Bold denotes biologics in development or approved

TD-8236 shown to potently inhibit targeted mediators of Th2-high and Th2-low asthma in human cells in preclinical studies

- Novel approved biologics address only Th2-high asthma
- Key treatment needs: Prevention of exacerbations and symptom control for patients regardless of Th2 phenotype

Phase 1 study data in healthy volunteers and mild asthmatics (including biomarker measures) expected 3Q19

Simpson JL, et al. Resp 2006;11:54-61.


Economic Interest
GSK's FDA-approved TRELEGY ELLIPTA (FF/UMEC/VI):
First and only once-daily single inhaler triple therapy

GSK's TRELEGY ELLIPTA

FIRST AND ONLY ONCE-DAILY SINGLE INHALER TRIPLE THERAPY

Economic interest in TRELEGY ELLIPTA

- Upward-tiering royalty of ~5.5% - 8.5% of worldwide net sales[1]
- Passive economic interest; no product cost obligations

Growth continues after first full year on market

- Available in 30 markets, including recent Japan launch
- Additional geographies expected in 2019; potential for China approval and launch later this year
- Phase 3 asthma study met primary endpoint; data to be submitted for regulatory review once full dataset available



Theravance Biopharma
Medicines That Make a Difference

TRELEGY ELLIPTA is FF/UMEC/VI or fluticasone furoate/umeclidinium/vilanterol; comprised of ICS, LAMA, and LABA, active components of Breo (FF/VI) and Anoro (UMEC/VI).
[1] TBPH holds 85% economic interest in upward-tiering royalty stream of 6.5% – 10% payable by GSK (net of TRC LLC expenses paid and the amount of cash, if any, expected to be used by TRC pursuant to the TRC LLC Agreement over the next four fiscal quarters). All statements based on publically available information.
sNDA: supplemental new drug application

Non-recourse PhaRMA℠ 9% Fixed Rate Term Notes

SECURITIZED BY ROYALTIES DUE ON NET SALES OF TRELEGY ELLIPTA

Transaction generated cash with retained economics

- December 2018 TBPH executed a non-dilutive private placement of $250M[1] PhaRMA℠ 9% fixed rate term notes
- Debt payable by economic interest in TRELEGY ELLIPTA[2]
  - 75% of royalties pledged to repay debt
  - 25% of royalties retained by TBPH
- Proceeds support key strategic priorities
- Following repayment of notes, all TRELEGY ELLIPTA related cash flows revert to TBPH

Non-recourse notes with flexible repayment terms

- Notes fully securitized by royalties due on net sales of TRELEGY ELLIPTA; no debt obligation to TBPH
- Quarterly interest obligations:
  - Through October 15, 2020, to the extent there are insufficient funds to satisfy quarterly interest payments, interest may be paid in-kind without a default or event of default occurring; or
  - At TBPH's option, quarterly interest payments may be satisfied by making a capital contribution for no more than 4 consecutive quarterly interest payment dates or for no more than 6 quarterly interest payment dates during the term of the notes

TRELEGY ELLIPTA is FF/UMEC/VI or fluticasone furoate/umeclidinium/vilanterol; comprised of ICS, LAMA, and LABA, active components of Breo (FF/VI) and Anoro (UMEC/VI).
[1]Net proceeds (excluding $12.5 million of retained notes and other fees related to the transaction) were approximately $230 million [2]TBPH holds 85% economic interest in upward-tiering royalty stream of 6.5% – 10% payable by GSK (net of TRC LLC expenses paid and the amount of cash, if any, expected to be used by TRC pursuant to the TRC LLC Agreement over the next four fiscal quarters).

Arbitration Against Innoviva, Inc. (INVA)

TBPH INTENDS TO ENFORCE ALL RIGHTS TO TRELEGY ELLIPTA ROYALTIES[1]

The Respiratory Company, LLC (TRC LLC)

- Upon our spin-off from INVA in 2014, TBPH and INVA entered into a binding limited liability company agreement
- TRC LLC is jointly owned by TBPH and INVA but managed by INVA
- TBPH entitled to 85% and INVA entitled to 15% of royalties paid to TRC LLC by GSK resulting from GSK's net sales of TRELEGY ELLIPTA
- Agreement imposes express fiduciary duties on INVA and significant limitations on INVA's authority as manager

Arbitration underway

- In May 2019, we initiated arbitration against INVA and TRC LLC due to INVA's failure to disburse stipulated royalties to TBPH
  - INVA has caused TRC LLC to not remit royalty payments for 4Q18; and
  - INVA has stated it intends to cause TRC LLC to withhold cash distributions for the remainder of 2019
- TBPH intends to enforce all aspects of the agreement to ensure we continue receiving our 85% share of TRELEGY-related royalties
- Agreement stipulates parties shall use commercially reasonable best efforts to complete arbitration within 90 days after the arbitrator(s) is/are appointed
- We are confident that the arbitration process provides an expedient forum to resolving the dispute in our favor
- Confidentiality provisions limit what we can communicate publicly about this matter. We have and will continue to abide by those confidentiality provisions, which require all parties to keep this matter confidential, subject to any non-waivable disclosure obligations under applicable law

TRELEGY ELLIPTA is FF/UMEC/VI or fluticasone furoate/umeclidinium/vilanterol; comprised of ICS, LAMA, and LABA, active components of Breo (FF/VI) and Anoro (UMEC/VI).
[1]TBPH holds 85% economic interest in upward-tiering royalty stream of 6.5% – 10% payable by GSK (net of TRC LLC expenses paid and the amount of cash, if any, expected to be used by TRC pursuant to the TRC LLC Agreement over the next four fiscal quarters).


Opportunities for Value Creation
Upcoming milestones

Focus on Strategic Priorities

COMMITMENT TO CREATING TRANSFORMATIONAL MEDICINES

Opportunities to Create Transformational Medicines	YUPELRI®	**Nebulized LAMA in COPD** • Formal commercial launch underway
	TD-1473	**Intestinally-restricted JAKi for inflammatory intestinal diseases** • Phase 2 DIONE study in Crohn's disease underway • Phase 2b/3 RHEA study in ulcerative colitis underway • Supplemental Phase 1b data to be shared in oral presentation at DDW
	Ampreloxetine	**NRI in symptomatic neurogenic orthostatic hypotension** • Registrational Phase 3 program progressing • 5-month data from Phase 2 in nOH to be shared at IAPRD and ENC
	TD-8236	**Lung-selective inhaled pan-JAK inhibitor for serious respiratory diseases** • Safety and biomarker data from Phase 1 study in healthy volunteers and asthmatic patients expected 3Q19
Economic Interest	TRELEGY ELLIPTA[1]	**(FF/UMEC/VI) Single inhaler triple therapy in COPD** • Product launched in 30 markets, including Japan; additional geographies expected throughout 2019 (incl. China) • Positive results from Phase 3 CAPTAIN study in patients with asthma recently announced • Potential sNDA in 2H 2019

Significant existing cash resources to fund strategic priorities[2]

[1] TBPH holds 85% economic interest in upward-tiering royalty stream of 6.5% – 10% payable by GSK (net of TRC LLC expenses paid and the amount of cash, if any, expected to be used by TRC pursuant to the TRC LLC Agreement over the next four fiscal quarters). All statements based on publically available information.
[2] Cash of approximately $434M as of March 31, 2019 (cash, cash equivalents, and marketable securities)

About YUPELRI® (revefenacin) inhalation solution

YUPELRI® (revefenacin) inhalation solution is a novel once-daily nebulized LAMA approved for the maintenance treatment of COPD in the US. Market research by Theravance Biopharma indicates approximately 9% of the treated COPD patients in the US use nebulizers for ongoing maintenance therapy.[1] LAMAs are a cornerstone of maintenance therapy for COPD and YUPELRI is positioned as the first once-daily single-agent bronchodilator product for COPD patients who require, or prefer, nebulized therapy. YUPELRI's stability in both metered dose inhaler and dry powder device formulations suggest that this LAMA could also serve as a foundation for novel handheld combination products.

[1] TBPH market research (N = 160 physicians); refers to US COPD patients

YUPELRI® (revefenacin) inhalation solution

Important Safety Information (US)

YUPELRI is contraindicated in patients with hypersensitivity to revefenacin or any component of this product.

YUPELRI should not be initiated in patients during acutely deteriorating or potentially life-threatening episodes of COPD, or for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta2-agonist.

As with other inhaled medicines, YUPELRI can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs following dosing with YUPELRI, it should be treated immediately with an inhaled, short-acting bronchodilator. YUPELRI should be discontinued immediately and alternative therapy should be instituted.

YUPELRI should be used with caution in patients with narrow-angle glaucoma. Patients should be instructed to immediately consult their healthcare provider if they develop any signs and symptoms of acute narrow-angle glaucoma, including eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema.

Worsening of urinary retention may occur. Use with caution in patients with prostatic hyperplasia or bladder-neck obstruction and instruct patients to contact a healthcare provider immediately if symptoms occur.

Immediate hypersensitivity reactions may occur after administration of YUPELRI. If a reaction occurs, YUPELRI should be stopped at once and alternative treatments considered.

The most common adverse reactions occurring in clinical trials at an incidence greater than or equal to 2% in the YUPELRI group, and higher than placebo, included cough, nasopharyngitis, upper respiratory infection, headache and back pain.

Coadministration of anticholinergic medicines or OATP1B1 and OATP1B3 inhibitors with YUPELRI is not recommended.

YUPELRI is not recommended in patients with any degree of hepatic impairment.